Toronto Dominion Bank Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Toronto Dominion Bank lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.6% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 54,719 shares of the biopharmaceutical company's stock after purchasing an additional 1,378 shares during the period. Toronto Dominion Bank's holdings in Regeneron Pharmaceuticals were worth $57,523,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $127,489,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in shares of Regeneron Pharmaceuticals by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company's stock valued at $525,804,000 after buying an additional 96,266 shares during the period. TD Asset Management Inc lifted its holdings in Regeneron Pharmaceuticals by 30.4% in the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company's stock valued at $369,484,000 after acquiring an additional 82,034 shares during the last quarter. Finally, Icon Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock worth $79,874,000 after acquiring an additional 75,569 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on REGN. Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a research report on Thursday, October 24th. Citigroup began coverage on shares of Regeneron Pharmaceuticals in a report on Thursday, November 14th. They issued a "neutral" rating and a $895.00 price objective on the stock. Oppenheimer lowered their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a research note on Wednesday, November 6th. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. Finally, Cantor Fitzgerald restated a "neutral" rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $1,099.90.

Regeneron Pharmaceuticals Stock Down 4.1 %

Shares of Regeneron Pharmaceuticals stock traded down $32.03 during trading hours on Thursday, hitting $740.97. The company had a trading volume of 923,616 shares, compared to its average volume of 555,558. The company's 50-day moving average is $860.87 and its two-hundred day moving average is $1,007.41. Regeneron Pharmaceuticals, Inc. has a twelve month low of $735.95 and a twelve month high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company has a market cap of $81.43 billion, a P/E ratio of 19.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.08.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.